A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)

A Single-Center, Open-Label Phase II Clinical Study to Evaluate the Antiviral Activity and Immune Responses of AHB-137 Injection in Participants With CHB Treated With Nucleos (t) Ide Analogues

A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) (NCT06993480) is a Phase 2 interventional studying Chronic Hepatitis B, sponsored by Ausper Biopharma Co., Ltd.. RECRUITING as of the most recent ClinicalTrials.gov update. Talk to your doctor before contacting the trial site.

About This Trial

What Stage of Research Is This?

Phase 2 trials evaluate whether a treatment actually works against Chronic Hepatitis B and continue monitoring side effects. Phase 2 enrolls larger groups (typically 100–300 patients) and produces the first real efficacy signal. A successful Phase 2 readout is what unlocks the much larger Phase 3 confirmatory trials needed for FDA approval.

This trial is currently recruiting participants. The sponsor has registered the study with ClinicalTrials.gov as actively enrolling, which means new applicants who meet the eligibility criteria can be considered for screening. Trial status can change between updates — confirm current recruiting status with the study contact before traveling for a screening visit.

With a target enrollment of 30 participants, this is a small study — typical of early-phase research, rare-disease trials, or pilot studies designed to generate preliminary signal before a larger study is launched.

Who May Be Eligible (Plain English)

Who May Qualify: - Voluntarily participated in the study and signed an willing to sign a consent form form; - Aged between 18 and 55 years at the time of signing the willing to sign a consent form form; - Body mass index (BMI) within the range of 18-30 kg/ m2; - HBeAg negative or positive at screening; - HBsAg or HBV DNA positive for at least 6 months; - Have been on continuous nucleos(t)ide analogues antiviral therapy for more than 6 months prior to screening; - 100 IU/mL \< HBsAg ≤ 3000 IU/mL and HBV DNA \< 100 IU/mL at screening; - Alanine aminotransferase (ALT) ≤ 2 × upper limit of normal (ULN); - Effective contraception as required. Who Should NOT Join This Trial: - Clinically significant abnormalities other than a history of CHB infection; - Concomitant clinically significant other liver diseases; - Any serious infection other than CHB infection requiring intravenous anti-infective therapy within 1 month prior to screening; - Active hepatitis C, Human weakened immune system virus (HIV) positive, syphilis positive; - Liver stiffness value (LSM) \> 9.0 kPa at screening; - Diagnosis or suspicion of hepatocellular carcinoma, or alpha-fetoprotein (AFP) concentration ≥ 20 ng/mL at screening; - Participants with confirmed or suspected hepatic decompensated hepatitis B cirrhosis; - Liver biopsy at screening assessed severity of activity ≥ G3 grade and/or fibrosis reaching S4 stage; - History of extrahepatic disease possibly related to HBV immune status; ...See full criteria on ClinicalTrials.gov Always talk to your doctor about whether this trial is right for you.

These are translations of the protocol\'s inclusion and exclusion criteria, simplified for patients and caregivers. The original clinical text appears below. Eligibility is ultimately confirmed by the trial site\'s screening process — this summary is a starting point for a conversation with your doctor, not a final determination.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Voluntarily participated in the study and signed an informed consent form; * Aged between 18 and 55 years at the time of signing the informed consent form; * Body mass index (BMI) within the range of 18-30 kg/ m2; * HBeAg negative or positive at screening; * HBsAg or HBV DNA positive for at least 6 months; * Have been on continuous nucleos(t)ide analogues antiviral therapy for more than 6 months prior to screening; * 100 IU/mL \< HBsAg ≤ 3000 IU/mL and HBV DNA \< 100 IU/mL at screening; * Alanine aminotransferase (ALT) ≤ 2 × upper limit of normal (ULN); * Effective contraception as required. Exclusion Criteria: * Clinically significant abnormalities other than a history of CHB infection; * Concomitant clinically significant other liver diseases; * Any serious infection other than CHB infection requiring intravenous anti-infective therapy within 1 month prior to screening; * Active hepatitis C, Human immunodeficiency virus (HIV) positive, syphilis positive; * Liver stiffness value (LSM) \> 9.0 kPa at screening; * Diagnosis or suspicion of hepatocellular carcinoma, or alpha-fetoprotein (AFP) concentration ≥ 20 ng/mL at screening; * Participants with confirmed or suspected hepatic decompensated hepatitis B cirrhosis; * Liver biopsy at screening assessed severity of activity ≥ G3 grade and/or fibrosis reaching S4 stage; * History of extrahepatic disease possibly related to HBV immune status; * Ongoing or taking any immunosuppressive medication within 3 months prior to screening. Those who have used immunomodulators and cytotoxic drugs within 6 months prior to the first dose, or have a history of vaccination within 1 month prior to screening or have a live vaccination plan during the trial; Continuous use of traditional Chinese medicine for more than 2 months within 1 year prior to screening, or within 1 month prior to screening; Ongoing use of anticoagulants, bleeding tendency or coagulopathy, or conditions that, in the opinion of the investigator, increase the risk of liver biopsy; * Receiving or using any interferon-containing therapy within 12 months prior to screening; * History of malignancy within 5 years prior to screening or being evaluated for possible malignancy; * Suspected history of allergy to any component of the study drug, or allergic constitution (multiple drug and food allergy, and judged by the investigator to be clinically significant); * Major trauma or major surgery within 3 months prior to screening, or planned surgery during the study; * Donation or blood loss ≥ 400 mL, or received blood transfusion within 12 weeks prior to screening; Or blood donation or blood loss ≥ 200 mL within 1 month prior to screening; * Participants who are participating in another clinical trial, or have not undergone a protocol-specified washout period prior to this study; * Received any antisense oligonucleotides (ASO) or using any small molecule interfering ribonucleic acid (siRNA) drug within 12 months prior to screening; * Participants with abnormal thyroid function judged by the investigator to be ineligible for enrollment; * Obviously abnormal laboratory test results; * History of vasculitis or signs and symptoms of underlying vasculitis; * Any other circumstance or condition that, in the opinion of the investigator, the participants are inappropriate for participation in the study.

Treatments Being Tested

DRUG

AHB-137

AHB-137 300 mg will be injected subcutaneously once a week (total 24 weeks).

Locations (1)

Trial sites listed on ClinicalTrials.gov for this study. Site activation status can vary — confirm with the specific site before traveling for a screening visit.

The Second Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

How to Talk to Your Doctor About This Trial

Bring the printable summary of this trial — including the NCT ID (NCT06993480), the sponsor (Ausper Biopharma Co., Ltd.), and the key eligibility criteria — to your next appointment. Your doctor can review the inclusion and exclusion criteria against your medical history, lab values, and current treatments to assess whether you are likely to qualify. They can also help you weigh whether trial participation makes sense alongside your existing care plan.

Useful questions to walk through together: What does the trial protocol require beyond standard care? How long is the active treatment phase, and how long is follow-up? Are there study visits at sites I can reach? Who pays for the trial-specific procedures, and who pays for standard-of-care portions? See our 25 questions to ask about clinical trials guide for a more complete checklist.

Authoritative Sources

The official record for this trial lives on ClinicalTrials.gov — the federal registry maintained by the National Library of Medicine at NIH. For background on how this trial fits into the FDA approval pathway, see the FDA drug approval process. For oncology-specific guidance for patients considering trials, the National Cancer Institute publishes patient-oriented overviews. International trial registries are aggregated by the WHO ICTRP.

Frequently Asked Questions

What is the NCT06993480 clinical trial studying?

AB-10-8005 is a single-center, open-label Phase II clinical study to evaluate the antiviral activity and immune responses of AHB-137 injection in participants with CHB treated with nucleos (t) ide analogues. The full protocol is registered on ClinicalTrials.gov and includes the primary outcome measures, eligibility criteria, and study endpoints.

Who can participate in NCT06993480?

Eligibility for this trial depends on the specific inclusion and exclusion criteria set by the sponsor. The plain-English summary above translates the most important criteria into accessible language; the official clinical text is preserved in the collapsible section underneath. Whether you fit any specific trial is a medical decision your doctor needs to confirm — bring the trial information to your treating physician for a full review against your medical history.

How do I contact the trial site for NCT06993480?

Contact information registered with ClinicalTrials.gov is shown in the sidebar of this page. Before reaching out, confirm with your treating physician that this trial is appropriate for your situation. The trial site will then walk you through the screening process to determine final eligibility.

Is participating in a clinical trial safe?

Clinical trials in the United States are regulated by the FDA and overseen by Institutional Review Boards (IRBs) that review the protocol for safety. Risk varies by trial — Phase 1 studies test new treatments in humans for the first time, while Phase 3 trials use treatments that have already passed earlier safety screening. The informed consent document for any specific trial details the known risks and what to expect. Discuss those risks with your physician before deciding whether to participate.

Where can I verify the data on this page?

Every detail on this page comes directly from the ClinicalTrials.gov API. Click "View on ClinicalTrials.gov" in the sidebar to see the official, unmodified record. The federal record is always authoritative; this page is a structured presentation with a plain-English eligibility translation. For background on how clinical trials are regulated, see the FDA drug approval process documentation.

How This Page Is Built

Every field on this page is pulled directly from the ClinicalTrials.gov API v2 — no estimates, no proxies. The plain-English eligibility translation is generated from the original protocol text and reviewed for fidelity to the underlying clinical criteria. The original clinical text remains visible in the collapsible section above so users and clinicians can verify the translation. Read the full methodology for the data pipeline and known limitations.

Source: ClinicalTrials.gov API v2 record for NCT06993480. Maintained by the National Library of Medicine at NIH. Public domain. Cite as: "TrialFinderData. NCT06993480. Data: ClinicalTrials.gov."

Medical disclaimer: This page is informational, not medical advice. Talk to your doctor about whether a clinical trial is right for you.

Last updated 2026-05-08 · Data from ClinicalTrials.gov.